Member Info for M_Night

Paraytec alone is worth more than the current 16mil mcap, let alone the other investments.

A 16mil mcap for a new groundbreaking testing solution that can be used for COVID, Sepsis and Cancer and no doubt other diseases too is far too low. Not to mention other projects they are cooking up in that lab of theirs.

The last RNS showed clearly this is a commercially viable solution, with production partners finalised and multiple commercial partners in late stage discussions. At the prices they quoted, demand will be high for it across many sectors.

For a well funded tech stock in the medical sector, this is ridiculously undervalued and I have no doubt there is plenty of domestic and international interest here.

I am personally confident either the technology or Paraytec itself will be sold to a bigger player in this space and shareholders or BRH will reap the rewards. 16mil mcap is a great entry price, especially whilst Covid is here to stay well into next year.

BRH is funding Paraytec and their project because they know its about to deliver a return that is mulitples of their investment. That's the great thing about developing new cutting edge technologies.

Background buying continues. Jump in all. Updates galore and sale of the test will land soon.

A super duper special dividend galore and a 100p+ share price awaits again in early 2022.

MMs ticking things up. News due any day now and people loading up in the background. Especially before the January fireworks.

Hey, a company on aim with actual growing revenues, partnerships with the worlds biggest companies, that has bucket loads of cash and is now has the scalability to grow quickly.

A low share offering to boot with this being 13p in Jan of this year. What's not to love here?

All the investments they have made about to bear fruit. Can see 60p+

Yes, existing holders won't get many shares and those that do, it will only average them down ever so slightly. There won't be many sellers at this level with multiple bits of big news landing any day now.

Background buys sneaking in.

I see, definitely more tricky to diagnose!

But I imagine this technology can be expanded and developed over time to other diseases that need fast detection too.

Covid, Sepsis, Cancer Alzheimer's these are all the biggest killers in the world and this test is proven to work against them all, whilst being portable and just £1500 per unit!!!!

Mcap will be in the hundreds of millions once the deals are struck, as they are for tech and medical companies.

https://youtu.be/1DtSUjgnmqY
https://youtu.be/PniHlp5MNJc

135p was hit at the beginning of 2021.

I can see this hitting the 100p+ range again at the beginning of 2022.

Some of these 3rd round discussions with the prospective partners they mentioned will be close to being finalised now.

Bought in here.

Test partner deal to be announced soon. Absolute bargain at this mcap for a new innovating and leading COVID, bladder cancer, Sepsis and Alzheimer's test.

Big rewards to reap all.

I don't many traders appreciate the magnitude of recent developments. They are company defining moments and clearly more are to come. Even simply announcing who the AAA publisher is.

Look at how much news has flooded in over the past 3-4 months. This momentum is going to continue and traders are going to be caught out time and time again.

At this level, it would be simply better to build a decent position and hold it for the long-term. Well into next year to see where this goes.

Good luck all.

The vast majority of those shares will simply be averaging down others pre-existing holding and so actually I wouldn't expect many sellers at this level.

Production updates are coming now. We got the additional CE mark last week.

Good times ahead.

Gonna be an absolute monster.

Electronic Arts all but confirmed. Just saying.

+ "However, revenue for the year will be significantly higher than last year (FY20: £1.7m)."

BIDS $wimming in $.

No placing.

Year end cash at £7mil, as per the RNS.

Now massive revenues coming, minimum figure of 30mil for FY 22 and 23, as per the RNS. Watch these scale up quickly through their model, more deals and by beating their minimum target.

That's plenty of headroom for a small cap company to expand without needing extra funds at this level. Other AIM companies would dream of being in this situation.

Honestly not a wild expectation. The other disclosed AAA publisher is most definitely EA.

Imagine now trying to pitch their advertising solutions to the other big publishers and thousands of studios and smaller developers all over the world.

When you have EA and AAA publishers in your portfolio, like Azerion, they'll be able to secure so many more partnerships with ease.

Thousands of game publishers. Tens of thousands of games. Hundreds of millions of players. Hundreds of billions in revenue each year.

AAA publishers giving Bidstack exclusive multi-year agreements.

If this was listed in the US, the mcap would be 5-10x based on potential alone.

Fantastic opportunity here in an exciting tech stock now with proven and growing revenue streams and multiple incoming partnerships within a few months.

They have proven their tech to the best and now we will get an epic re-rate over the months and year ahead.

Don't sit on this. We all know the games industry is the biggest entertainment sector in the world.

Weekend exposure and others cluing on they have an AAA publisher on board, very likely EA, will make this gap up Monday am.